AMPH vs BCRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AMPH · Amphastar Pharmaceuticals$28.49 ▲ 3.00%
BCRX · BioCryst Pharmaceuticals$7.69 ▲ 0.79%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AMPH +9.1%
- BCRX +6.8%
Head to head
| Metric | AMPH | BCRX |
|---|---|---|
| Price | $28.49 | $7.69 |
| Change today | ▲ 3.00% | ▲ 0.79% |
| Market cap | $1.22B | $1.98B |
| Return, 3 months | +40.3% | -21.8% |
| Return, year to date | +6.4% | -1.4% |
| Return, 1 year | +18.6% | +8.5% |
| P/E (TTM) | 13.1 | – |
| P/B | 1.5 | -5.0 |
| P/E percentile vs own 5y | 55th | 69th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5.4% | +33.6% |
| Net profit growth (YoY) | -2.2% | +1,441.7% |
| Gross margin | 47.7% | 97.8% |
| Operating margin | 15.7% | -33.3% |
| Net margin | 10.8% | -40.9% |
| Return on equity | 10.3% | – |
| Analyst target vs. price | -27.2% | +154.5% |
| Analyst buy share | 0% | 71% |
| RSI (14) | 67 | 41 |
| 30-day volatility | 34.7% | 45.1% |
| Max drawdown, 1 year | -42.6% | -31.3% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BCRX is the largest of the group by market value.
- AMPH has returned the most over the past year.
- BCRX is growing revenue fastest.
- AMPH keeps the most profit per dollar of sales.
- AMPH has been the calmest stock over the last 30 days.